EMA recommends approval of two improved COVID-19 vaccines
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
EMA recommends approval of two improved COVID-19 vaccines
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The European Medicines Agency (EMA) recommends approval of two improved COVID-19 vaccines.
On September 1, the European Medicines Agency recommended the approval of two improved vaccines against the mutated new coronavirus Omicron strain BA.1, saying that it can be used as a booster shot for people aged 12 and over who have completed the initial vaccination.
The European Medicines Agency said that the two improved vaccines are based on the Comirnaty vaccine produced by the American Pfizer Pharmaceutical Co., Ltd. and the German biotech company and the Spikevax vaccine produced by the American Moderna company.
In addition to the new coronavirus strain, it can also act on the spike protein of the mutant new coronavirus Omicron strain BA.1.
Studies have shown that vaccination with an improved version of the vaccine 3 months after the initial vaccination can stimulate a strong immune response against the BA.
On the one hand, it is more effective than the initial vaccine. Side effects of the improved vaccine are comparable to those of the original vaccine and are usually mild and short-lived.
The agency said marketing recommendations for the two improved vaccines would be submitted to the European Commission for final approval.
The European Medicines Agency explained that with the development of the COVID-19 epidemic, the EU’s strategy is to provide a series of improved vaccines against multiple new coronavirus mutant strains, so that member states can have multiple options when formulating vaccination strategies.
Since it is impossible to predict how the virus will mutate in the future and which mutated strains will be prevalent this winter, this strategy is critical to the EU’s overall strategy to deal with the COVID-19 epidemic.
The European Medicines Agency also stated that improved vaccines against Omicron subtype strains such as BA.4 and BA.5 are currently being tested, and some will be submitted soon. If approved, it will further expand the available vaccine resources.
The European Medicines Agency said that the current Comirnaty and Spikevax vaccines remain effective in preventing severe illness, hospitalization and death related to the new coronavirus and will continue to be used for vaccinations in the EU, especially as initial vaccinations.
EMA recommends approval of two improved COVID-19 vaccines
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
